Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03627403 · ClinicalTrials.gov registry record · Phase 2
Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
A Phase 2 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT03627403 is a Phase 2 study that was terminated before completion, run by University of Utah. The registered enrollment target is 17 participants.
The verdict
NCT03627403, a Phase 2 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is a phase II, open label, prospective, single-arm study evaluating the efficacy and safety of selinexor in patients with PMF or secondary MF (PPV-MF or PET-MF) who are refractory or intolerant to ruxolitinib and/or any other experimental JAK1/2 inhibitors.
Interventions
- DRUG Selinexor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-05-10 |
| Est. Completion | 2025-03-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03627403
The ClinicalTrials.gov registry entry for NCT03627403 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Selinexor is the first listed.
NCT03627403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03627403 about?
NCT03627403 is a clinical study titled "Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors". This is a phase II, open label, prospective, single-arm study evaluating the efficacy and safety of selinexor in patients with PMF or secondary MF (PPV-MF or PET-MF) who are refractory or intolerant to ruxolitinib and/or any other experimental JAK1/2 inhibitors.
What is the current status of trial NCT03627403?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2019-05-10. Estimated completion is 2025-03-05.
What interventions are being tested in trial NCT03627403?
The interventions under investigation include: Selinexor (DRUG).
Who is sponsoring clinical trial NCT03627403?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.